| 名稱 | BCR(E13)-ABL1(E2)_P210 Fusion |
| 型號(hào) | CBP20207R |
| 報(bào)價(jià) |  |
| 特點(diǎn) | BCR(E13)-ABL1(E2)_P210 Fusion |
產(chǎn)品搜索
相關(guān)文章
- 淺談NTRK fusion
- RNA-Fusion Cocktail再升級(jí)
- 大腦中新發(fā)現(xiàn)的一種淋巴細(xì)胞，能夠清除大腦廢物
- 選擇性組蛋白去乙?；敢种苿┰谀[瘤免疫治療中的作用及前景
- ATCC細(xì)胞的實(shí)驗(yàn)要點(diǎn)及說(shuō)明
- 腸道守護(hù)者--GLP2R
- 強(qiáng)強(qiáng)聯(lián)合！IBM與MIT開(kāi)展腫瘤藥物抗藥性研究
- 黃金賽道——CDH17靶點(diǎn)
- PD-1/PD-L1:研發(fā)過(guò)剩還是大有可為
- OX40&PD-1/L1雙免疫檢查點(diǎn)細(xì)胞篩選模型
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
基因檢測(cè)標(biāo)準(zhǔn)品 > Fusion > CBP20207RBCR(E13)-ABL1(E2)_P210 Fusion
- 詳細(xì)內(nèi)容
CBP20207R | |
| Format | RNA |
| Description | Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. |
| Technical Data | |
| Left Gene | BCR |
| Right Gene | ABL1 |
| Left Breakpoint | chr22:23631808:+（hg19） |
| Right Breakpoint | chr9:133729451:+（hg19） |
| Buffer | Tris-EDTA |
| Product Information | |
| Intended Use | Research Use Only |
| Unit Size | 1ug |
| Concentration | Download for COA |
| Purity | Download for COA |
| RNA electrophoresis | Download for COA |
| Sanger sequencing |
|
| Storage | -80℃ |
| Expiry | 12 months from the date of manufacture |
會(huì)員_a.png)